Evidence map›Paper›PMID 34603293›Full record

ArticleFrontiers in immunology2021

Construction of a Ferroptosis-Related Nine-lncRNA Signature for Predicting Prognosis and Immune Response in Hepatocellular Carcinoma.

Zhijie Xu, Bi Peng, Qiuju Liang, Xi Chen, Yuan Cai, Shuangshuang Zeng, Kewa Gao, Xiang Wang, Qiaoli Yi, Zhicheng Gong and 1 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 135 papers.

0numbers the graph read from it
0cells of the map it votes in
135citing papers in PubMed
18.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

135 citing papers in PubMed, 230 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Review
  15. Alteration in CaMolecular biology reports · 2025
    Article
  16. Review
  17. Article
  18. Article
  19. Review
  20. Article

75 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Zhijie XuDepartment of Pathology, Xiangya Hospital, Central South University, Changsha, China.
Bi PengDepartment of Pathology, Xiangya Hospital, Central South University, Changsha, China.
Qiuju LiangDepartment of Pharmacy, Xiangya Hospital, Central South University, Changsha, China.
Xi ChenDepartment of Pharmacy, Xiangya Hospital, Central South University, Changsha, China.
Yuan CaiDepartment of Pathology, Xiangya Hospital, Central South University, Changsha, China.
Shuangshuang ZengDepartment of Pharmacy, Xiangya Hospital, Central South University, Changsha, China.
Kewa GaoDepartment of Pathology, Xiangya Hospital, Central South University, Changsha, China.
Xiang WangDepartment of Pharmacy, Xiangya Hospital, Central South University, Changsha, China.
Qiaoli YiDepartment of Pharmacy, Xiangya Hospital, Central South University, Changsha, China.
Zhicheng GongDepartment of Pharmacy, Xiangya Hospital, Central South University, Changsha, China.
Yuanliang YanDepartment of Pharmacy, Xiangya Hospital, Central South University, Changsha, China.
Central South University · CNXiangya Hospital Central South University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ferroptosis is an iron-dependent cell death process that plays important regulatory roles in the occurrence and development of cancers, including hepatocellular carcinoma (HCC). Moreover, the molecular events surrounding aberrantly expressed long non-coding RNAs (lncRNAs) that drive HCC initiation and progression have attracted increasing attention. However, research on ferroptosis-related lncRNA prognostic signature in patients with HCC is still lacking. In this study, the association between differentially expressed lncRNAs and ferroptosis-related genes, in 374 HCC and 50 normal hepatic samples obtained from The Cancer Genome Atlas (TCGA), was evaluated using Pearson's test, thereby identifying 24 ferroptosis-related differentially expressed lncRNAs. The least absolute shrinkage and selection operator (LASSO) algorithm and Cox regression model were used to construct and validate a prognostic risk score model from both TCGA training dataset and GEO testing dataset (GSE40144). A nine-lncRNA-based signature (CTD-2033A16.3, CTD-2116N20.1, CTD-2510F5.4, DDX11-AS1, LINC00942, LINC01224, LINC01231, LINC01508, and ZFPM2-AS1) was identified as the ferroptosis-related prognostic model for HCC, independent of multiple clinicopathological parameters. In addition, the HCC patients were divided into high-risk and low-risk groups according to the nine-lncRNA prognostic signature. The gene set enrichment analysis enrichment analysis revealed that the lncRNA-based signature might regulate the HCC immune microenvironment by interfering with tumor necrosis factor α/nuclear factor kappa-B, interleukin 2/signal transducers and activators of transcription 5, and cytokine/cytokine receptor signaling pathways. The infiltrating immune cell subtypes, such as resting memory CD4(+) T cells, follicular helper T cells, regulatory T cells, and M0 macrophages, were all significantly different between the high-risk group and the low-risk group as indicated in Spearman's correlation analysis. Moreover, a substantial increase in the expression of B7H3 immune checkpoint molecule was found in the high-risk group. Our findings provided a promising insight into ferroptosis-related lncRNAs in HCC and a personalized prediction tool for prognosis and immune responses in patients.

Indexed as

RNA, Long NoncodingBiomarkers, TumorCarcinoma, HepatocellularCell Line, TumorComputational BiologyDatabases, Nucleic AcidDisease SusceptibilityFerroptosisGene Expression ProfilingHumansImmunityLipid PeroxidationLiver NeoplasmsLymphocytes, Tumor-InfiltratingPrognosisProportional Hazards ModelsBiomarkers, TumorRNA, Long Noncodingferroptosishepatocellular carcinomaimmune cell infiltratelncRNAsurvival analysis

Identifiers

PMID34603293
PMCPMC8484522
OpenAlexW3201346550

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.